Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
基本信息
- 批准号:10637251
- 负责人:
- 金额:$ 64.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-23 至 2028-01-31
- 项目状态:未结题
- 来源:
- 关键词:ATF6 geneAcuteAftercareAllelesAntibodiesAntibody ResponseAntibody titer measurementApoptosisApoptoticAutoantibodiesAutoimmunityB-LymphocytesBindingBiochemicalBlood VesselsBone MarrowBone Marrow CellsCationsCell DeathCell SurvivalCell physiologyCellsConnexinsCre driverCuesDataDiseaseElementsEndothelial CellsEndotheliumExposure toFamilyFosteringHealthHomeostasisHomingHost DefenseHumanHumoral ImmunitiesImmunoglobulin AImmunoglobulin GIn SituIn VitroInfectionLongevityMammalsMediatingMetabolicMitochondriaModelingMutagenesisMutationNewborn InfantOsteoblastsOutcomePathogenicityPathway interactionsPharmaceutical PreparationsPlasma CellsPlayProcessProtein BiosynthesisPurinoceptorRegulationRoleSerumSignal TransductionSourceSpleenStromal Cell-Derived Factor 1TestingTransplantationVaccinationVaccinesWorkXBP1 genebonebone losscell typechemokineendoplasmic reticulum stressextracellularimprovedimproved outcomeinhibitorinsightnovel strategiespreventresponserestrainttranscription factor CHOP
项目摘要
Project summary
Antibody-secreting plasma cells play critical roles in health and disease, yet little is known
about the biochemical mechanisms controlling antibody synthesis and secretion or how
these pathways intersect with pathways controlling cell survival. Furthermore, due to the
high metabolic demands inherent to robust antibody secretion and the tendency for many
plasma cells to persist for decades, pathways restraining apoptosis in plasma cells are
likely to be integrated in unique ways. This project centers on the hypothesis that long-
lived plasma cells in bone marrow obtain requisite signals to maintain antibody secretion
and avoid cell death by sensing extracellular ATP with a purinergic receptor known as
P2rX4. We further hypothesize that eATP is produced locally in the bone marrow for
plasma cells by osteoblastic cells via the gap junction protein known as Panx3. Thus,
consistent with our preliminary data, inhibition of P2rX4 or Panx3 function is predicted to
cause the depletion of long-lived plasma cells and reduce serum antibody titers including
for disease-associated antibodies. To test our hypothesis, we will: 1) Define cell intrinsic
P2rX4-regulated outcomes for newborn and long-lived plasma cells, and 2) Define cell
extrinsic sources and outcomes for eATP/Panx3 regulation of long-lived plasma cells.
These studies will provide unique and needed insights into the specialized survival
mechanisms employed by long-lived plasma cells. This work supports our long-term
objective of developing strategies to effectively and specifically disable or deplete
problematic plasma cells.
项目摘要
分泌抗体的浆细胞在健康和疾病中起关键作用,但鲜为人知
关于控制抗体合成和分泌的生化机制,或
这些途径与控制细胞存活的途径相交。此外,由于
强大的抗体分泌固有的高代谢需求和许多人的趋势
血浆细胞要持续数十年,限制血浆细胞凋亡的途径是
可能以独特的方式整合。该项目以以下假设为基础
骨髓中的血浆细胞获得必要的信号以维持抗体分泌
并通过使用称为嘌呤能受体的细胞外ATP来避免细胞死亡
P2RX4。我们进一步假设eatp是在骨髓中本地生产的
成骨细胞通过间隙连接蛋白称为panx3的血浆细胞。因此,
与我们的初步数据一致,预计P2RX4或PANX3功能的抑制作用为
导致长寿命的浆细胞的耗竭,并减少血清抗体滴度(包括)
用于疾病相关的抗体。为了检验我们的假设,我们将:1)定义细胞固有的
P2RX4调节的新生儿和长期浆细胞的结果,2)定义细胞
长寿命浆细胞调节EATP/PANX3的外在来源和结果。
这些研究将为专业生存提供独特的和必要的见解
长寿命浆细胞采用的机制。这项工作支持我们的长期
制定策略以有效,专门禁用或耗尽的策略
有问题的浆细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M Allman其他文献
David M Allman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M Allman', 18)}}的其他基金
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10215534 - 财政年份:2020
- 资助金额:
$ 64.81万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10443660 - 财政年份:2020
- 资助金额:
$ 64.81万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10652461 - 财政年份:2020
- 资助金额:
$ 64.81万 - 项目类别:
Epigenetic Control of Plasma Cell Differentiation
浆细胞分化的表观遗传控制
- 批准号:
9105812 - 财政年份:2015
- 资助金额:
$ 64.81万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Targeting urinary tract dysfunctions after spinal cord injury with epidural stimulation
通过硬膜外刺激治疗脊髓损伤后的尿路功能障碍
- 批准号:
10656916 - 财政年份:2023
- 资助金额:
$ 64.81万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 64.81万 - 项目类别:
Enhancing Hypnotic Medication Discontinuation in Primary Care through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
通过监督药物逐渐减量和数字认知行为失眠治疗,加强初级保健中催眠药物的停药
- 批准号:
10736443 - 财政年份:2023
- 资助金额:
$ 64.81万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 64.81万 - 项目类别:
Resources, Workforce Development, and Animal Models for the Rutgers RBL
罗格斯大学 RBL 的资源、劳动力发展和动物模型
- 批准号:
10793863 - 财政年份:2023
- 资助金额:
$ 64.81万 - 项目类别: